Pam3CSK4

• Description:

  Pam3CSK4 is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2[1].

• Product Name Alternative:

  Pam3Cys-Ser- (Lys) 4

• UNSPSC:

  12352209

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Toll-like Receptor (TLR)

• Type:

  Peptides

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pam3csk4.html

• Solubility:

  H2O

• Smiles:

  CCCCCCCCCCCCCCCC (OCC (OC (CCCCCCCCCCCCCCC) =O) CSC[C@H] (NC (CCCCCCCCCCCCCCC) =O) C (N[C@@H] (CO) C (N[C@@H] (CCCCN) C (N[C@@H] (CCCCN) C (N[C@@H] (CCCCN) C (N[C@H] (C (O) =O) CCCCN) =O) =O) =O) =O) =O) =O

• Molecular Formula:

  C81H156N10O13S

• Molecular Weight:

  1510.23

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  Staphylococcus aureus

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• Isoform:

  TLR1; TLR2

• Citation 01:

  Antiviral Res. 2022 Jul:203:105346.|Biochem Biophys Res Commun. 2024 Apr 16:704:149661.|Int Immunopharmacol. 2022 May:106:108613.|Microbes Infect. 2024 Jan-Feb;26 (1-2) :105244.|Mol Immunol. 2021 Feb;130:85-95.|Sci Rep. 2023 Nov 9;13 (1) :19440.|Chin Herb Med. 2024 Apr 30;16 (3) :422-434.|Int Immunopharmacol. 2022 Dec;113 (Pt A) :109312.|J Pharm Anal. 2025 Jan;15 (1) :101054.|Nat Immunol. 2025 Oct;26 (10) :1660-1672.|Phytomedicine. 2025 Jun:141:156705.|PLoS Pathog. 2024 Nov 5;20 (11) :e1012614.|Sci China Life Sci. 2024 Dec;67 (12) :2664-2677.|Sci Rep. 2022 Oct 12;12 (1) :17058.

• CAS Number:

  112208-00-1